Clinical trials · Texas
Refractory Cancer clinical trials in Texas
We’re tracking 75 recruiting refractory cancer studies with a site in Texas — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06235801RecruitingPhase 1/Phase 2
Combination targeted therapy for relapsed FLT3-mutated leukemia
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
Houston, TexasAges 18 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Houston, TexasAges 12 years+ - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT06906900RecruitingPhase 1
Device therapy for spinal tumors that have stopped responding to treatment
This trial tests a wearable device that puts low-intensity electric fields on the skin over spinal tumors to slow their growth. It's for people whose spinal metastases have already been treated with surgery and/or radiation and have no more radiation options.
Houston, TexasAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Houston, TexasAges 12 years+ - NCT06213311RecruitingPhase 2
CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Houston, TexasAges 18 years+ - NCT06466395RecruitingPhase 1
Hyper-CVAD plus venetoclax for relapsed pediatric leukemia
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
Houston, TexasAges 2–21 - NCT05529069RecruitingPhase 2
Testing pirtobrutinib plus venetoclax for relapsed mantle cell lymphoma
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Houston, TexasAges 18 years+ - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Dallas, TexasAges 12–39 - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Houston, TexasAges 12 years+ - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT07032727RecruitingPhase 2
Olutasidenib plus targeted therapy for relapsed IDH1-mutated myeloid cancers
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Houston, TexasAges 18 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT05910801RecruitingPhase 2
Tafasitamab plus lenalidomide and venetoclax for relapsed lymphoma
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Houston, TexasAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Houston, TexasAges 18 years+ - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Austin, TexasAges 6 months–22 years
Refractory Cancer trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting refractory cancer studies listed above.
- The University of Texas MD Anderson Cancer Center · 21 studies
- Baylor College of Medicine · 2 studies
- University of Texas Southwestern Medical Center · 2 studies
- Baylor Scott & White Memorial Hospital
- Children's Hospital of San Antonio
- Dell Children's Medical Center of Central Texas
- El Paso Children's Hospital
- MD Anderson Cancer Center
What taking part in a refractory cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Refractory Cancer trials in other states
Common questions
- Are there refractory cancer clinical trials in Texas?
- Yes. We're currently tracking 75 recruiting refractory cancer studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory cancer study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory cancer studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.